BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development. The Company plans to seek guidance in Q3 2025 ...

Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin ...

WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the ...

Fractyl has built its patent portfolio since 2011, and its IP estate now includes 31 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and ...

Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership ...

Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise. Company Also Hires ...

The 113th Congress of Japan Society of Aesthetic Surgery Venue：The Okura Tokyo Dates：Wednesday, May 28 – Friday, May 30, 2025 ...

Saudi biotech startup Novo Genomics signed two major agreements: one with Tracer Biotechnologies to localize ctDNA monitoring ...

COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of ...

Standard Health is a clinical healthcare provider, responsible for site development and operation of the facility with Smith+Nephew supplying its innovative portfolio of medical technologies. Standard ...

Larry Nichols, Chief Executive Officer of Steri-Tek, commented: " The integration of IBA's Be Wide X-ray Solution into our newest facility is a transformative step, enhancing our ability to serve ...

All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Biomea. The gross proceeds to Biomea from the offering, before deducting underwriting ...